ICMRA statement on need for continued focus on COVID-19 therapeutics

ICMRA urges all stakeholders, including researchers, pharmaceutical industry, healthcare professionals, health research funding agencies and research institutions, to continue their focus on developing therapeutics to treat and prevent COVID-19 in patients around the world. In a joint statement, ICMRA members highlight the continued need for safe, effective and high-quality COVID-19 treatments for all populations, including those who are underrepresented or underserved, and those living in low- and middle-income countries.

ICMRA statement on need for continued focus on COVID-19 therapeutics (10 December 2021)

Statement in other languages

• French - Déclaration de l’ICMRA sur la nécessité de continuer à mettre l’accent sur les produits thérapeutiques pour la COVID-19
• Japanese - COVID-19治療薬に対する継続した取り組みの必要性に関するICMRAステートメント